There is growing interest in treating breast cancer with hypofractionated postmastectomy radiotherapy (PMRT). National patterns of hypofractionated PMRT utilization were assessed using the National Cancer Database. Overall, hypofractionated PMRT use was uncommon although it increased over time. Hypofractionated PMRT was used in patients more likely to gain convenience from shorter treatment schedules. Background: The acceptance of hypofractionated radiotherapy in treating breast cancer in the breast conservation therapy setting has stimulated interest in hypofractionated postmastectomy radiotherapy (PMRT). We assessed national trends and patterns of utilization of hypofractionated PMRT. Patients and Methods: Women 18 years of age or older with breast cancer treated with mastectomy and PMRT to the chest wall with or without regional lymph nodes from 2004 to 2014 were identified from the National Cancer Database. A standard fractionation cohort was defined as patients receiving 180 to 200 cGy per fraction to a total dose of 4500 to 7000 cGy over 5 to 7 weeks, and a hypofractionation cohort was defined as those receiving 250 to 400 cGy per fraction to a total dose of 3000 to 6000 cGy over 2 to 5 weeks. Multivariable logistic regression was used to determine factors associated with hypofractionated PMRT use. Results: We identified 113,981 patients who met study criteria. Overall, hypofractionated PMRT use was low (1.1%) although utilization increased over time (P .001). Older age, greater comorbidity, further distance from treatment facility, treatment at academic facilities, less extensive disease, and recent treatment year were statistically significant predictors of hypofractionation use compared with standard fractionation. Conversely, breast reconstruction and receipt of chemotherapy were negative predictors. Conclusion: Because of the absence of high-level evidence to support its use, hypofractionated PMRT was uncommonly utilized in the United States from 2004 to 2014, although a small increase in use was noted over time. Findings from this study might be useful in designing future studies, and might serve as a baseline for evaluation of future changes in practice patterns.
Introduction
It is well established that postmastectomy radiotherapy (PMRT) improves long-term outcomes by reducing the risk of breast cancer recurrence in patients with high-risk features. [1] [2] [3] PMRT is typically delivered to the chest wall and regional lymph nodes using standard fractionation regimens consisting of 180 to 200 cGy per fraction over 5 to 7 weeks. 4 However, there is a growing interest in delivering PMRT with hypofractionated regimens, which consist of a larger dose per fraction but fewer total fractions, possibly spurred by the successful adoption of such regimens in the breast conservation setting. 4, 5 The rationale for treating breast cancer with hypofractionated radiotherapy is primarily twofold. First, the overall treatment course is shortened without sacrificing treatment efficacy, which might result in greater patient convenience and lower cost to health systems. 6, 7 Second, radiobiological data suggest that breast cancer compared with standard doses. 8 However, these considerations must be balanced by the potential for increased long-term toxicities such as poor cosmesis, lymphedema, cardiopulmonary injury, brachial plexopathy, and rib fracture. Although multiple trials with extensive follow-up have convincingly shown equivalent disease control and toxicity between hypofractionated and standard radiotherapy in the breast conservation setting, [9] [10] [11] [12] [13] there is a paucity of such data for chest wall and regional lymph node irradiation in the postmastectomy setting. The best long-term evidence supporting hypofractionated PMRT comes from the United Kingdom START (Standardisation of Breast Radiotherapy) trials, 9, 10 in which approximately 12% of patients (513 of 4451) were treated with PMRT to the chest wall and regional lymph nodes. Ten-year results of these trials showed no significant differences in shoulder stiffness and arm edema between patients who received hypofractionation versus standard fractionation radiotherapy, and the incidence of symptomatic pneumonitis or brachial plexopathy was rare (< 1%)-only 1 patient in the START A trial treated with hypofractionated PMRT developed brachial plexopathy. 9, 14 More recently, results from a phase II trial of 69 patients treated with hypofractionated PMRT in the United States showed that hypofractionated PMRT might be safe and effective. 15 The favorable results from this trial have provided the impetus for the development of a phase III randomized trialAlliance A221505-which seeks to compare outcomes after hypofractionated PMRT versus standard fractionation PMRT in a large cohort of women. Considering the growing interest in hypofractionated PMRT and the limited data regarding its use in the United States, we conducted an observational study using a national cancer registry to assess temporal trends and patterns of utilization of hypofractionated PMRT in women treated for breast cancer between 2004 and 2014. Findings from this study might aid in the design of future studies and might serve as a basis for comparison of future changes in practice patterns with regard to hypofractionated PMRT. We hypothesized that use of hypofractionated PMRT would be uncommon overall, but that there might be an increase in use over time, perhaps because of the increased acceptance of hypofractionation in the breast-conservation setting during the same time period.
Patients and Methods

Data Source
The study cohort was identified from the National Cancer Database (NCDB), 16 
Study Population
Inclusion criteria ( Figure 1 ) consisted of women 18 years of age or older with invasive, nonmetastatic breast carcinoma treated with mastectomy followed by adjuvant external beam radiotherapy directed to the chest wall with or without inclusion of regional lymph nodes. From this population, a standard fractionation cohort and a hypofractionation cohort were identified. The standard fractionation cohort consisted of patients who received 180 to 200 cGy per fraction to a total dose of 4500 to 7000 cGy over 5 to 7 weeks whereas the hypofractionation cohort consisted of patients who received 250 to 400 cGy per fraction to a total dose of 3000 to 6000 cGy over 2 to 5 weeks. Because initial and boost doses of radiotherapy were not robustly delineated in the NCDB, the aforementioned dose ranges might or might not be inclusive of a boost. Patients who did not meet criteria for either cohort, or those who received radiotherapy as part of palliative care, were excluded from the analysis.
Variables
Covariates examined included age, race, population density of patient residence (classified as metropolitan, urban, or rural), facility type (community or academic), patient distance to facility, geographic location of facility, primary insurance coverage, level of educational attainment (defined as percentage of the population in the patient's home ZIP code not achieving a high school degree), income (median income in the patient's home ZIP code), Charlson/ Deyo comorbidity score, 17 
Aims
The primary aim was to assess nationwide temporal trends and patterns of utilization of hypofractionated PMRT in women treated for breast cancer from 2004 to 2014. We also sought to identify patient-, facility-, and tumor-related factors that predicted for receipt of hypofractionation relative to standard fractionation.
Statistical Analysis
Baseline characteristics of patients who received hypofractionated and standard fractionation PMRT were compared using the Pearson c 2 test. A multivariable logistic regression model, that included all covariates meeting a threshold significance of P < .1 in univariable regression analysis, was created to assess the independent effect of each covariate on the odds of receiving hypofractionated versus standard fractionation PMRT.
A 2-sided P value of < .05 was used to determine statistical significance. All analyses were performed using Stata SE, version 14.0 (StataCorp, College Station, TX).
Results
Characteristics of the Overall Cohort
Baseline characteristics of the overall cohort are described in Table 1 . Of the 113,981 patients who met study criteria, 1305 (1.1%) were treated with hypofractionated PMRT whereas 112,676 (98.9%) were treated with a standard fractionation regimen. The median age of the entire cohort was 54 years (interquartile range [IQR], 46-64).
In the hypofractionation cohort, the median total dose delivered was 5000 cGy (IQR, 4256-5090 cGy) in 16 fractions (IQR, [15] [16] [17] [18] [19] [20] ; in the standard fractionation cohort, the median total dose 
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Clinical Breast Cancer October 2018 -e903 [28] [29] [30] [31] [32] [33] . The most commonly used doseefractionation regimen in the hypofractionated cohort was 4256 cGy in 16 fractions (266 cGy per fraction) which was used in 20% of the cohort, whereas the most common regimen in the standard fractionation cohort was 5040 cGy in 28 fractions (180 cGy per fraction) which was used in 52% of the cohort.
As shown in Table 1 , most patients were white (76%), treated at community centers (63%), presented with invasive ductal carcinoma (76%), and ER-positive disease (75%). Most patients underwent a modified radical mastectomy (56%) and received chemotherapy (87%).
Temporal Trends
The utilization of hypofractionated PMRT increased over time from 0.8% of patients receiving such treatment in 2004 to 1.7% of patients receiving it in 2014 (P trend < .001; Table 1 and Figure 2 (Table 2) . Over the study period, there was a more rapid increase in the utilization of hypofractionation at academic facilities compared with community facilities (Figure 2 ).
Factors Associated With Receipt of Hypofractionated PMRT
In multivariable analysis (Table 2) , notable factors associated with receipt of hypofractionated PMRT relative to standard fractionation were treatment at academic facilities compared with community facilities (odds ratio [OR], 1.84; 95% confidence interval [CI], 1.62-2.09; P < .001), greater degree of comorbidity (Charlson Deyo score 2 vs. 0; OR, 1.38; 95% CI, 1.04-1.82; P ¼ .024), older age ( 70 years vs. < 50 years; OR, 1.85; 95% CI, 1.47-2.32; P < .001), black race relative to white race (OR, 1.21; 95% CI, 1.02-1.43; P ¼ .028), and greater distance from treatment facility (> 50 miles vs. 50 miles; OR, 1.37; 95% CI, 1.10-1.71; P ¼ .005).
Factors predictive of a decreased likelihood of receipt of hypofractionation compared with standard fractionation were aggressive disease features such as high pathologic T stage (T3 vs. T1; OR, 0.67; 95% CI, 0.56-0.79; P < .001), and node positivity (N3 vs. N0; OR, 0.51; 95% CI, 0.41-0.63; P < .001). In addition, more extensive treatment such as receipt of a modified radical mastectomy compared with a simple mastectomy (OR, 0.87; 95% CI, 0.77-0.98; P ¼ .022), receipt of breast reconstruction (OR, 0.78; 95% CI, 0.67-0.91; P ¼ .001), and receipt of chemotherapy (OR, 0.31; 95% CI, 0.26-0.35; P < .001) were negative predictors of receipt of hypofractionation. Other notable pathologic features such as tumor receptor status, tumor grade, and surgical margin status were not significant predictors.
Discussion
We examined temporal trends and patterns of utilization of hypofractionated PMRT in 113,981 women treated for breast cancer from 2004 to 2014. Our results show that the overall use of hypofractionation was low, as would be expected on the basis of slow acceptance of hypofractionation after lumpectomy during this period, 7, 20 and the paucity of data showing safety and efficacy after mastectomy. Hypofractionation was used predominantly at academic centers, in patients with less extensive disease, and in patients more likely to find a prolonged course of treatment challenging such as elderly patients, those with greater comorbidities, and those living far from treatment facilities. National utilization of hypofractionated radiotherapy after breast conservation surgery has been increasing 7, 20 because of randomized evidence that showed equivalency in outcomes between hypofractionation and standard fractionation regimens. [9] [10] [11] [12] [13] [14] These data have led to the adoption of hypofractionated radiotherapy by national guidelines 4,5 as a standard treatment option in the breastconservation setting. Because of this success, there is a growing global interest in using hypofractionation in the postmastectomy setting. At the present time, high-quality data regarding hypofractionated PMRT are scarce, although this approach is the subject of multiple ongoing phase II trials in the United States (ClinicalTrials.gov identifiers: NCT02515110, NCT02700386, NCT02912312), and at least 2 ongoing phase III trials internationally (ClinicalTrials.gov identifiers: NCT02690636, NCT00793962).
Previous work on hypofractionated PMRT is heterogeneous. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] In a prospective study from Egypt, Ali and AlMageed 31 reported on 47 patients randomized to either conventional (50 Gy in 25 fractions) or hypofractionated PMRT (42 Gy in 16 fractions); with a median follow-up time of 34 months; the authors reported equivalent disease control and cosmesis between study arms. In a prospective trial of 112 patients from Greece treated with hypofractionated PMRT consisting of 3.5 Gy fractions to a total dose of 35 Gy followed by a boost dose of 8 Gy in 2 fractions, Koukourakis et al 29 reported high rates of acute skin desquamation but good disease control at a median follow-up of 44 months. Shahid et al 26 retrospectively reviewed outcomes of 300 patients treated with PMRT with 2700 cGy in 5 fractions, 3500 cGy in 10 fractions, or patients with 36.63 Gy in 11 fractions followed by an optional boost using modern radiation techniques; with a median follow-up of 32 months, local recurrence-free survival was 89.2% and toxicity rates were acceptable and in line with previously published reports. These promising results have prompted the development of a phase III trial, Alliance A221505, which will aim to provide additional high-level evidence regarding the long-term efficacy and toxicity in patients treated with hypofractionated PMRT. Because there has been no clear evidence guiding the optimal use of hypofractionated PMRT, our study findings might reflect some of the complex forces that drive medical care in the United States. The significant increase in hypofractionated PMRT over the study period mirrors the uptake of hypofractionated treatment in the breast-conservation setting, 7, 20 although on a smaller scale, and might indicate extrapolation of data by providers from one setting to another. Increased utilization of hypofractionation at academic centers compared with community centers might suggest a greater familiarity and comfort with hypofractionated radiotherapy at academic centers, perhaps stemming from their more frequent use in the breast-conservation setting, 20 or a greater ease with deviating from guideline-based care. The greater use of hypofractionated PMRT in elderly patients, those with greater comorbidities, and those who live far from treatment show an inclination toward increasing patient convenience and alleviating the challenges associated with a long course of treatment. Previous work suggests that increasing patient convenience with hypofractionated radiotherapy improves patient compliance with treatment. 35 The greater likelihood of treating elderly patients might also reflect concerns about treating younger patients with hypofractionation because of the potential for increased long-term side effects when using larger doses per fraction, particularly with regard to cosmesis. It is worth noting, however, that such concerns have not materialized in the breast conservation setting with 15-year follow-up of the Canadian randomized trial.
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Our results also show that the overall use of hypofractionation was selective, likely reflecting a lack of clarity regarding optimal patient selection. The decreased likelihood of treating patients with node-positive disease with hypofractionation might reflect a concern that treating the regional lymph nodes with hypofractionation might increase the risk of lymphedema. 36 Our findings also suggest a reluctance to use hypofractionated PMRT in the setting of a breast reconstruction and previous chemotherapy use, both of which are settings in which further research is warranted to allay concerns regarding acute as well as chronic side effects. These questions, particularly those regarding outcomes after breast reconstruction, will be informed by the results of Alliance A221505, which will exclusively enroll patients with breast reconstruction after mastectomy. Our findings should be interpreted in light of certain limitations. First, there are a number of important variables that are not recorded by the NCDB. For instance, we do not have data regarding disease control outcomes or treatment toxicity, which are important end points to consider when evaluating hypofractionated radiotherapy. Additionally, we are also unable to directly assess other patient-, provider-, and facility-level variables such as patient and provider preferences, institutional practice patterns, or reimbursement patterns, which could have further informed our results. Second, there were certain variables, such as HER2 receptor status, that contained a significant proportion of missing information; therefore, findings regarding their association with hypofractionation should be interpreted cautiously. These limitations are offset by strengths of this study which include a large patient population, and the wide array of patient-, facility-, and treatment-level variables that were included in the analysis.
Conclusion
In the absence of high-level evidence to support its use, utilization of hypofractionated PMRT was low in patients with breast cancer identified from the NCDB from 2004 to 2014. There was, however, a small trend toward increased use over time. Older age, greater comorbidity, further distance to treatment, treatment at academic facilities, and less extensive disease were independent predictors of receipt of hypofractionated treatment. These data might serve as a baseline upon which to evaluate future changes in practice patterns that might occur with accrual of high-quality evidence regarding hypofractionated PMRT.
Clinical Practice Points
There is growing global interest in treating breast cancer with hypofractionated PMRT. However, data to guide optimal practice are limited by several factors including use of outdated radiotherapy techniques, use of variable hypofractionation schedules, limited follow-up times, and uncertain generalizability to practice in the United States. This study was performed to assess national trends and patterns of utilization of PMRT in the United States. Patients with nonmetastatic breast cancer who were treated with a mastectomy and PMRT were identified from the NCDB. The use of hypofractionated PMRT was very low (1.1%) but there was a significant increase in utilization over the study period. Factors associated with hypofractionated PMRT use were older age, greater comorbidity, further distance from treatment facility, treatment at academic facilities, less extensive disease, and more recent treatment year. Receipt of breast reconstruction surgery and chemotherapy were negative predictors. Promising results from the first dedicated North American hypofractionated PMRT study, a phase II trial, were recently published. These results have spurred the development of a phase III randomized controlled trial-Alliance A221505-which will assess the efficacy and safety of hypofractionated PMRT in a larger cohort of women.
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Results from this study provide an overview of recent patterns of care. This information might aid in designing future studies and might serve as a baseline upon which future changes in practice patterns with regard to hypofractionated PMRT are evaluated.
